Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Nuvalent, Inc.

NUVLNASDAQ
Healthcare
Biotechnology
$97.93
$-0.07(-0.07%)
U.S. Market opens in 13h 1m

Nuvalent, Inc. Fundamental Analysis

Nuvalent, Inc. (NUVL) shows weak financial fundamentals with a PE ratio of -17.27, profit margin of 0.00%, and ROE of -42.07%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

Cash Position18.65%
Current Ratio15.27

Areas of Concern

ROE-42.07%
Operating Margin0.00%
We analyze NUVL's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -17.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-17.6/100

We analyze NUVL's fundamental strength across five key dimensions:

Efficiency Score

Weak

NUVL struggles to generate sufficient returns from assets.

ROA > 10%
-30.11%

Valuation Score

Excellent

NUVL trades at attractive valuation levels.

PE < 25
-17.27
PEG Ratio < 2
1.73

Growth Score

Weak

NUVL faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-81.11%

Financial Health Score

Excellent

NUVL maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
15.27

Profitability Score

Weak

NUVL struggles to sustain strong margins.

ROE > 15%
-4206.93%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is NUVL Expensive or Cheap?

P/E Ratio

NUVL trades at -17.27 times earnings. This suggests potential undervaluation.

-17.27

PEG Ratio

When adjusting for growth, NUVL's PEG of 1.73 indicates fair valuation.

1.73

Price to Book

The market values Nuvalent, Inc. at 5.89 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

5.89

EV/EBITDA

Enterprise value stands at -21.95 times EBITDA. This is generally considered low.

-21.95

How Well Does NUVL Make Money?

Net Profit Margin

For every $100 in sales, Nuvalent, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-42.07 in profit for every $100 of shareholder equity.

-42.07%

ROA

Nuvalent, Inc. generates $-30.11 in profit for every $100 in assets, demonstrating efficient asset deployment.

-30.11%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-3.66 in free cash annually.

$-3.66

FCF Yield

NUVL converts -3.84% of its market value into free cash.

-3.84%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-17.27

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

1.73

vs 25 benchmark

P/B Ratio

Price to book value ratio

5.89

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

15.27

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.42

vs 25 benchmark

ROA

Return on assets percentage

-0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.31

vs 25 benchmark

How NUVL Stacks Against Its Sector Peers

MetricNUVL ValueSector AveragePerformance
P/E Ratio-17.2728.25 Better (Cheaper)
ROE-42.07%780.00% Weak
Net Margin0.00%-20122.00% (disorted) Weak
Debt/Equity0.000.30 Strong (Low Leverage)
Current Ratio15.274.66 Strong Liquidity
ROA-30.11%-14687.00% (disorted) Weak

NUVL outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Nuvalent, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-1505.46%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-1295.94%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ